CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)

Clinical trial NCT04637763 · UNKNOWN

Trial details

NCT number: NCT04637763
Sponsor: Caribou Biosciences, Inc.
Status: UNKNOWN
Phase: Phase 1
Study type: INTERVENTIONAL

Lymphoma, Non-Hodgkin Relapsed Non Hodgkin Lymphoma Refractory B-Cell Non-Hodgkin Lymphoma Non Hodgkin Lymphoma Lymphoma B Cell Lymphoma B Cell Non-Hodgkin's Lymphoma

Start date: 2021-05-26
Primary completion: 2025-08-01
Enrollment: 72

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.